Clinical TrialAug 6, 2026, 08:08 AM
Compass Therapeutics Tovecimig Phase 2/3 Met ORR, PFS Endpoints
AI Summary
Compass Therapeutics announced positive survival and safety data from its Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel for biliary tract cancer. The study met its primary endpoint of overall response rate (18.0% vs 5.3%) and secondary endpoint of progression-free survival (4.7 months vs 2.6 months). The company anticipates FDA feedback in Q3 2026 for a potential Biologics License Application filing later this year. For the six months ended June 30, 2026, the company reported a net loss of $(43.471) million, with cash, cash equivalents, and marketable securities totaling $180 million, providing a runway into 2028.
Key Highlights
- Tovecimig Phase 2/3 COMPANION-002 met primary ORR endpoint (18.0% vs 5.3%).
- Tovecimig Phase 2/3 met secondary PFS endpoint (4.7 months vs 2.6 months).
- FDA feedback on COMPANION-002 expected Q3 2026 for potential BLA filing.
- Net loss for six months ended June 30, 2026, was $(43.471) million.
- Research and development expenses increased to $32.968 million for six months.
- Total cash, cash equivalents, and marketable securities were $180 million.
- Cash resources expected to fund operating expenses into 2028.
Price Impact
More from CMPX